一项评价乌帕替尼在中国青少年和成人中重度特应性皮炎(AD)患者中的安全性和有效性的前瞻性、多中心、上市后观察性研究
[Translation] A prospective, multicenter, post-marketing observational study to evaluate the safety and efficacy of upadacitinib in Chinese adolescents and adults with moderate-to-severe atopic dermatitis (AD)
评价乌帕替尼在真实世界临床实践中,用于中国青少年(≥12至<18岁)和成人(≥18岁)中重度特应性皮炎(AD)患者的安全性和有效性。
[Translation] To evaluate the safety and efficacy of upadacitinib in Chinese adolescents (≥12 to <18 years old) and adults (≥18 years old) with moderate to severe atopic dermatitis (AD) in real-world clinical practice.
100 Clinical Results associated with AbbVie Srl
0 Patents (Medical) associated with AbbVie Srl
100 Deals associated with AbbVie Srl
100 Translational Medicine associated with AbbVie Srl